The Summary
Two phase 3 randomized, double-blind trials (evoke and evoke+) evaluated oral semaglutide (up to 14 mg daily) versus a placebo in 3,808 participants aged 55 to 85 with early-stage Alzheimer's disease. Over 104 weeks, researchers tracked changes in cognitive function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Ultimately, the trials were discontinued early; semaglutide demonstrated no significant difference in cognitive decline compared to the placebo, meaning the drug failed to meet its primary efficacy goal, though its safety profile remained consistent with prior studies.
Why this is interesting
Excitement has built around GLP-1 receptor agonists—popularly known for diabetes and metabolic benefits—due to database studies suggesting they might protect against dementia. However, these rigorous clinical trials show that oral semaglutide does not slow Alzheimer's progression once early symptoms have set in. For patients and families, this clarifies that while GLP-1 drugs have immense therapeutic value for metabolic health, they are not a silver bullet for treating active Alzheimer's disease, highlighting the ongoing need for targeted neurological therapies.